Last reviewed · How we verify
NCT02785744
Genzyme Osteopenia/Osteoporosis Study
trial testing Gaucher disease DNA mutation analysis in Gaucher Disease in 76 participants. Completed in 1 September 2019.
1 September 2019
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 76 |
| Start date | 1 April 2016 |
| Primary completion | 1 September 2019 |
| Estimated completion | 1 September 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Gaucher disease DNA mutation analysis
Conditions studied
- Gaucher Disease — all drugs for Gaucher Disease →
Sponsor
NYU Langone Health — full company profile →
Who can join
18 and older, any sex, with Gaucher Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease. The purpose of this research study is to determine the prevalence of Gaucher disease in patients with low bone mineral density as observed by DEXA scan, which is a form of X-Ray of the bone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02785744
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gaucher Disease
Currently open trials in the same condition.
- NCT06528080 — A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease · EARLY_PHASE1 · active not recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06539169 — FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases · recruiting
- NCT05843552 — Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease · recruiting
- NCT05487599 — A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) · Phase 1, PHASE2 · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02785744 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 23 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02785744.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing